A detailed history of Goldman Sachs Group Inc transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 447,317 shares of INZY stock, worth $1.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
447,317
Previous 361,868 23.61%
Holding current value
$1.35 Million
Previous $1.61 Million 45.01%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.31 - $6.0 $368,285 - $512,694
85,449 Added 23.61%
447,317 $2.34 Million
Q2 2024

Aug 13, 2024

SELL
$4.33 - $7.31 $208,078 - $351,282
-48,055 Reduced 11.72%
361,868 $1.61 Million
Q1 2024

May 15, 2024

BUY
$4.14 - $7.66 $192,721 - $356,580
46,551 Added 12.81%
409,923 $3.14 Million
Q4 2023

Feb 13, 2024

BUY
$2.71 - $4.5 $838,701 - $1.39 Million
309,484 Added 574.31%
363,372 $1.55 Million
Q3 2023

May 14, 2024

SELL
$4.09 - $7.0 $1.27 Million - $2.17 Million
-309,484 Reduced 85.17%
53,888 $226,000
Q3 2023

Nov 14, 2023

BUY
$4.09 - $7.0 $79,750 - $136,493
19,499 Added 56.7%
53,888 $226,000
Q2 2023

May 14, 2024

BUY
$4.93 - $6.74 $110,752 - $151,414
22,465 Added 188.4%
34,389 $191,000
Q2 2023

Aug 14, 2023

BUY
$4.93 - $6.74 $169,537 - $231,781
34,389 New
34,389 $191,000
Q4 2022

May 14, 2024

SELL
$1.05 - $2.82 $610 - $1,638
-581 Reduced 4.65%
11,924 $12,000
Q4 2022

Feb 13, 2023

BUY
$1.05 - $2.82 $12,520 - $33,625
11,924 New
11,924 $12,000
Q2 2022

May 14, 2024

SELL
$3.2 - $5.96 $1.12 Million - $2.09 Million
-350,867 Reduced 96.56%
12,505 $60,000
Q2 2022

Aug 15, 2022

SELL
$3.2 - $5.96 $2,400 - $4,470
-750 Reduced 5.66%
12,505 $60,000
Q1 2022

May 16, 2022

BUY
$3.87 - $7.55 $61 - $120
16 Added 0.12%
13,255 $54,000
Q4 2021

Feb 14, 2022

SELL
$5.58 - $11.5 $18,559 - $38,249
-3,326 Reduced 20.08%
13,239 $90,000
Q3 2021

Nov 10, 2021

BUY
$11.12 - $19.4 $184,202 - $321,361
16,565 New
16,565 $192,000

Others Institutions Holding INZY

About Inozyme Pharma, Inc.


  • Ticker INZY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,145,700
  • Market Cap $121M
  • Description
  • Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...
More about INZY
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.